A Drug Interaction Study of LY3871801 in Healthy Participants

Phase 1

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose up to 96 hours postdose

Awards & highlights

No Placebo-Only Group

Summary

This trial tests how a new oral drug, LY3871801, affects the levels of other medications in healthy people. It checks for any side effects and how well people tolerate LY3871801 over several weeks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose up to 96 hours postdose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose up to 96 hours postdose

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 96 hours postdose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Methotrexate

Dextromethorphan

+7 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: LY3871801 + Repaglinide + Drug Cocktail (Part 2)Experimental Treatment5 Interventions

LY3871801 administered orally in combination with repaglinide given orally and drug cocktail which includes warfarin, dextromethorphan and midazolam administered orally.

Group II: LY3871801 + Methotrexate (Part 1)Experimental Treatment2 Interventions

LY3871801 administered orally in combination with methotrexate given orally.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Warfarin

2017

Completed Phase 4

~248220

Repaglinide

2016